Abstract 6222: Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy
Alison L. Dickson(University of St Andrews), David J. Harrison(NHS Lothian), Greice M. Zickuhr(University of St Andrews), Ruth Plummer(National Health Service), Mustafa Elshani(University of St Andrews), Stefan N. Symeonides(Edinburgh Cancer Research), Sarah P. Blagden(Churchill Hospital), Natalie Cook(Manchester Academic Health Science Centre), In Hwa Um(University of St Andrews), Ying Zhang(Xijing Hospital), T.R. Jeffry Evans(University of Glasgow)
Cited by 1
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
High-frequency developmental abnormalities in p53-deficient mice
|Current Biology|1995|467
Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory
|Proceedings of the National Academy of Sciences|2007|421